Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2)

Next Previous
X
Search
Trial Profile

Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Docetaxel; Trastuzumab
  • Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms GAIN-2

    • Most Recent Events

    • 01 Feb 2021 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 Interim results of safety and interim invasive disease-free survival presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=598) assessing pathological complete response, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top